A clinical-stage immunotherapy company today announced positive phase 2 results in its metastatic pancreatic cancer clinical study in third-line or greater subjects showing that the overall survival (OS) rate for patients continues to be double compared to historical survival rates after two or more prior lines of therapy.
This news from ImmunityBio, Inc. is essential since pancreatic cancer is the fourth leading cause of cancer-related death (8.2%), with the five-year survival rate for late-stage cases being just 3%.
Read More
